TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18979547
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2, i.v. infusion for 3 consecutive weeks followed by 1-week rest)
Study: 12195873
Drug: Pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 400 mg b.i.d.
Study: 8040170
Drug: Balanced analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced analgesic regime with NSAID and continuous extrapleural intercostal nerve block
Study: 23204039
Drug: control (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (topical therapies or phototherapy)
Study: 16974199
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg GHB (Xyrem)
Study: 9051093
Drug: G‐CSF, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF, 300 micrograms subcutaneously
Study: 9051093
Drug: G‐CSF, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF, 600 micrograms subcutaneously
Study: 9051093
Drug: Dexamethasone, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 8 mg orally
Study: 9051093
Drug: G‐CSF, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF, 300 micrograms subcutaneously plus dexamethasone, 8 mg orally
Study: 9051093
Drug: G‐CSF, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF, 600 micrograms subcutaneously plus dexamethasone, 8 mg orally
Study: 9051093
Drug: Dexamethasone (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (any dose)
Study: 8312118
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy (BEP)
Study: 8312118
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with irradiation
Study: 8312118
Drug: Extended field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended field irradiation with weekly cisplatin
Study: 8312118
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy prior to pelvic radiotherapy
Study: 31549519
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and exercise (MET)
Study: 21930719
Drug: Improved antihypertensive
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved antihypertensive treatment
Study: 18426345
Drug: Ertapenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (1 g)
Study: 16551150
Drug: Positive therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive therapeutic relationship early in treatment
Study: 1388091
Drug: Etodolac 300
Normalized name: etodolac 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 300 mg TID (900 mg/day)
Study: 1388091
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg BID (1000 mg/day)
Study: 30131256
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release niacin (ERN) 1500–2000 mg/d
Study: 26597421
Drug: Multi-component hospital
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component hospital pharmacist-led behavioural counselling and/or pharmacotherapy
Study: 22980576
Drug: AFO/footwear combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFO/footwear combination
Study: 20438786
Drug: 1,25(OH)(2)D(3) treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)(2)D(3) treatment
Study: 15522756
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 45S5 bioactive glass (10% solution), applied daily (2 x 1 h) during the preventive and therapeutic phase (21 days non-hygiene phase and 7 days therapeutic phase)
Study: 15522756
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 45S5 bioactive glass (10% solution)
Study: 2358274
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aulhorn flicker test and VEP
Study: 391257
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (1200 mg daily for 7 days)
Study: 25254902
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine and fentanyl 2 μg/ml
Study: 25254902
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 μg/ml alone
Study: 21270174
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) A (600 μmol/L)
Study: 21270174
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) B (900 μmol/L)
Study: 14983962
Drug: Initial PSA
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial PSA < 4 ng/mL
Study: 14983962
Drug: Initial PSA
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial PSA < 1 ng/mL, age < 55 years, first 18 months
Study: 14983962
Drug: Initial PSA
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial PSA > 2.5 ng/mL, age < 55 years
Study: 10929878
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg p.o. 3 h after sucralfate (2 g)
Study: 10929878
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg p.o. 3 h after ferrous sulphate (325 mg)
Study: 10929878
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg p.o. 2 h before sucralfate
Study: 10929878
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg p.o. 2 h before ferrous sulphate
Study: 30269898
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of whey protein microgels (WPM30)
Study: 30269898
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of whey protein microgels (WPM50)
Study: 30269898
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g micellar casein (MC50)
Study: 29029015
Drug: Tapentadol 100
Normalized name: tapentadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol 100 mg
Study: 29029015
Drug: Tapentadol 150
Normalized name: tapentadol 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol 150 mg
Study: 15265255
Drug: ABC/COM (abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC/COM (abacavir 300 mg + lamivudine 150 mg/zidovudine 300 mg combination tablet)
Study: 15265255
Drug: IDV/COM (indinavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDV/COM (indinavir 800 mg + lamivudine 150 mg/zidovudine 300 mg combination tablet)
Study: 11975764
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg daily at bedtime
Study: 11975764
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg each evening
Study: 9043473
Drug: Dietary advice
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary advice and protein‐rich supplements for 4 months
Study: 7938088
Drug: Potassium depletion
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium depletion treatment (KD1, KD2, KD3)
Study: 7938088
Drug: Potassium depletion
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium depletion treatment (KD2, KD3)
Study: 7938088
Drug: Potassium depletion
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium depletion treatment (KD3)
Study: 31679408
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 200 mg dissolved in water
Study: 23281842
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ergocalciferol treatment)
Study: 23003342
Drug: Azithromycin smart
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin smart gel system (formulated with Pluronic® F‐127 and Hydroxy Ethyl Cellulose)
Study: 15931642
Drug: Acetate-free biofiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate-free biofiltration (AFB) with polyacrilonitrile filters for 4 hr thrice-weekly
Study: 2157554
Drug: CDDP (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP (120 mg/m2 x 3 weeks)
Study: 2157554
Drug: CDDP (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP (120 mg/m2) and VP‐16 (100 mg/m2 given i.v. on days 1‐3, repeated every 3 weeks)
Study: 2157554
Drug: CDDP (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP (120 mg/m2), VP‐16 (100 mg/m2 on days 1‐3), and mitomycin C (10 mg/m2 on days 1, 21, and 42, then every 6 weeks, for a maximal dose of 100 mg)
Study: 2157554
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CDDP/VP‐16)
Study: 27402283
Drug: Ice application
Normalized name: Camphor Ice Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice application with scheduled over-the-counter analgesics (n=36)
Study: 27402283
Drug: Scheduled over-the-counter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled over-the-counter analgesics alone (n=32)
Study: 17651830
Drug: Hydration with
Normalized name: Gold Bond Healing Hydration with Aloe Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration with 0.45% sodium chloride and acetylcysteine (1200 mg orally, twice loading dose at 12 hours before and immediately after procedure) in patients with elevated baseline creatinine.
Study: 12460293
Drug: Novel lidocaine/tetracaine‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel lidocaine/tetracaine‐based cream peel (S‐Caine)
Study: 12460293
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream with occlusion for 30 minutes
Study: 8748192
Drug: Triple-hormone infusion
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple-hormone infusion (epinephrine, glucagon, hydrocortisone)
Study: 1823392
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium for 2 days followed by oral magnesium (n = 12)
Study: 27976374
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy for PTSD (CT-PTSD)
Study: 26098004
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment (early discharge followed by home treatment in combination with inpatient treatment)
Study: 26098004
Drug: Regular length
Normalized name: Poise Pads Regular Length
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular length inpatient treatment (control group)
Study: 2532458
Drug: Cilazapril 1
Normalized name: cilazapril 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 1 mg once daily for 4 weeks, then increased to 2.5 mg once daily for 4 weeks, and further increased to 5 mg if necessary
Study: 1055560
Drug: DMSO spray
Normalized name: DMSO
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DMSO spray (2 ml applied in the posterior pharynx and tonsil region, 1 to 4 applications)
Study: 1055560
Drug: DMSO spray
Normalized name: DMSO
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DMSO spray
Study: 1055560
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar treatment without DMSO spray)
Study: 26099756
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CFNB and ITM
Study: 22746542
Drug: Artichoke leaf
Normalized name: artichoke leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke leaf extract (ALE) supplementation (250 mg, 2 b.i.d.)
Study: 21232162
Drug: Online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive behavioural therapy
Study: 19028952
Drug: 35 ml
Normalized name: ethanol 0.35 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 ml placebo gel
Study: 19028952
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g placebo rectal suppositories
Study: 1593410
Drug: Meclofenamate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate (100 mg)
Study: 6146164
Drug: Bromocriptine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2 mg)
Study: 30078111
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) + D-cycloserine (DCS)
Study: 30078111
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) + Placebo
Study: 22783709
Drug: Metamizol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol 1 g three times daily
Study: 22783709
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg twice daily
Study: 22783709
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g three times daily
Study: 20831534
Drug: Naloxone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone therapy
Study: 20831534
Drug: Naloxone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone administered parenterally by intermittent or continuous infusions
Study: 20831534
Drug: Infusion route
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion route of naloxone
Study: 17506732
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 60 mg IM
Study: 332319
Drug: Combination DTIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination DTIC plus methyl‐CCNU
Study: 6262148
Drug: Inactivated polio
Normalized name: Inactivated polio vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated polio vaccine (IPV) combined with concentrated diphtheria and tetanus toxoid, administered in one or two injections at an interval of 6 months.
Study: 6262148
Drug: Inactivated polio
Normalized name: Inactivated polio vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated polio vaccine C (higher concentration)
Study: 6262148
Drug: Oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polio vaccine (OPV), 4 doses in 15 months (control group)
Study: 30835956
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of autologous adipose-derived mesenchymal stem cells (AD-MSCs)
Study: 25135262
Drug: Fumaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaric acid 5% cream
Study: 21571394
Drug: Lowest balicatib
Normalized name: Balicatib
DrugBank: Balicatib (DB12239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest balicatib dose
Study: 15681524
Drug: Radiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation plus immediate androgen suppression (LHRH agonist)
Study: 15681524
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy and immediate hormonal manipulation
Study: 15119752
Drug: Loratadine 5
Normalized name: loratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 5 mg plus pseudoephedrine 120 mg
Study: 28403018
Drug: Methylatropine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylatropine (500 μg)
Study: 23919595
Drug: Buprenorphine implants
Normalized name: buprenorphine Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine implants (BI)
Study: 23919595
Drug: Placebo implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo implants (PI)
Study: 23919595
Drug: Sublingual buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine/naloxone tablets (BNX)
Study: 19226191
Drug: Prostacyclin (epoprostenol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin (epoprostenol, Flolan) at a dose of 0.5 ng/kg/min
Study: 15321031
Drug: Sol to
Normalized name: clobetasol topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sol to gel systems
Study: 10867450
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (120 mg, 40 mg t.i.d.)
Study: 3517076
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (pindolol 15 mg + hydrochlorothiazide 50 mg)
Study: 30803532
Drug: 3% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% tetracaine plus 0.05% oxymetazoline (Kovanaze) nasal spray and mock infiltration
Study: 30803532
Drug: Mock nasal
Normalized name: mockernut extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock nasal spray and 2% lidocaine with 1:100,000 epinephrine infiltration
Study: 25550228
Drug: Methylthioninium (MT)
Normalized name: Methylthioninium
DrugBank: Methylthioninium (DB08167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylthioninium (MT) 138 mg/day
Study: 25550228
Drug: Methylthioninium (MT)
Normalized name: Methylthioninium
DrugBank: Methylthioninium (DB08167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylthioninium (MT) 69 mg/day and 228 mg/day
Study: 20888912
Drug: Early rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early rapid corticosteroid reduction to 10 mg/day seven days post-transplantation
Study: 20888912
Drug: Standard corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard corticosteroid therapy
Study: 17520253
Drug: S-1 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 administered orally twice daily after meals at a dose of 80, 100, or 120 mg/day for body surface areas (BSAs) of less than 1.25 m(2), between 1.25 m(2) and less than 1.5, or 1.5 m(2) or greater, respectively, for 28 consecutive days, followed by a 14-day rest
Study: 12936917
Drug: Butter-enriched diet
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter-enriched diet (low in trans FAs, 2.6 g trans FAs/100 g fat)
Study: 12936917
Drug: Semiliquid margarine
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semiliquid margarine (0.6 g trans FAs/100 g fat)
Study: 12936917
Drug: Soft margarine
Normalized name: Soft margarine not polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft margarine (9.4 g trans FAs/100 g fat)
Study: 12936917
Drug: Shortening (13.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortening (13.6 g trans FAs/100 g fat)
Study: 12936917
Drug: Stick margarine
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stick margarine (26.1 g trans FAs/100 g fat)
Study: 9345420
Drug: 4.5 MIU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 MIU recombinant human interferon alfa-2a (Roferon-A) given thrice weekly for 6 months
Study: 9345420
Drug: 9.0 MIU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.0 MIU recombinant human interferon alfa-2a (Roferon-A) given thrice weekly for 6 months
Study: 9345420
Drug: Placebo given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given thrice weekly for 6 months
Study: 2052380
Drug: Caffeine with
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine with acetaminophen (2 combinations)
Study: 21290835
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and Acupuncture
Study: 11952187
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of applied relaxation, self‐control desensitization, and cognitive therapy
Study: 11952187
Drug: Interpersonal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal treatment (suggested addition)
Study: 8489058
Drug: Fentanyl at
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl at 3 ng/ml
Study: 8489058
Drug: Fentanyl at
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl at 10 ng/ml
Study: 7880699
Drug: Neostigmine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.07 mg kg‐1 (groups 1, 3, 5)
Study: 7880699
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg kg‐1 (groups 2, 4, 6)
Study: 2000827
Drug: dl‐alpha‐tocopherol 440
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl‐alpha‐tocopherol 440 mg
Study: 2000827
Drug: dl‐alpha‐tocopherol 880
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl‐alpha‐tocopherol 880 mg
Study: 2000827
Drug: dl‐alpha‐tocopherol 1320
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl‐alpha‐tocopherol 1320 mg
Study: 2000827
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of dl‐alpha‐tocopherol (440, 880, or 1320 mg/d for 28 d)